Terms: = Prostate cancer AND ATRX, P46100, ZNF-HX, XNP, XH2, SHS, SFM1, RAD54, MRXHF1, MGC2094, ATR2, 546 AND Prognosis
8 results:
1. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.
Sweeney C; Bracarda S; Sternberg CN; Chi KN; Olmos D; Sandhu S; Massard C; Matsubara N; Alekseev B; Parnis F; Atduev V; Buchschacher GL; Gafanov R; Corrales L; Borre M; Stroyakovskiy D; Alves GV; Bournakis E; Puente J; Harle-Yge ML; Gallo J; Chen G; Hanover J; Wongchenko MJ; Garcia J; de Bono JS
Lancet; 2021 Jul; 398(10295):131-142. PubMed ID: 34246347
[TBL] [Abstract] [Full Text] [Related]
2. Multiparametric Magnetic Resonance Imaging-Based Peritumoral Radiomics for Preoperative Prediction of the Presence of Extracapsular Extension With prostate cancer.
Bai H; Xia W; Ji X; He D; Zhao X; Bao J; Zhou J; Wei X; Huang Y; Li Q; Gao X
J Magn Reson Imaging; 2021 Oct; 54(4):1222-1230. PubMed ID: 33970517
[TBL] [Abstract] [Full Text] [Related]
3. Improving identification of candidates for lung cancer screening in a high risk population.
Waddle MR; Ko SJ; May J; Kaleem T; Miller DH; Stross WC; Malouff TD; Wert K; Cuthbert K; Landy R; Strong G; Vallow LA; Johnson MM
Lung Cancer; 2020 Oct; 148():79-85. PubMed ID: 32827761
[TBL] [Abstract] [Full Text] [Related]
4. The inflammation-related biomarker CXCR7 independently predicts patient outcome after radical prostatectomy.
Bargão Santos P; Lobo J; Félix A; Silva F; Manso RT; Costa JO; Lourenço B; Sequeira JP; Jerónimo C; Patel HHR; Henrique R
Urol Oncol; 2020 Oct; 38(10):794.e17-794.e27. PubMed ID: 32278731
[TBL] [Abstract] [Full Text] [Related]
5. Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT prostate multivariable model.
Thurtle DR; Greenberg DC; Lee LS; Huang HH; Pharoah PD; Gnanapragasam VJ
PLoS Med; 2019 Mar; 16(3):e1002758. PubMed ID: 30860997
[TBL] [Abstract] [Full Text] [Related]
6. High BIRC7 Expression Might Be an Independent Prognostic Indicator of Poor Recurrence-Free Survival in Patients With prostate cancer.
Yang Y; Sun P; Xu W; Xia W
Technol Cancer Res Treat; 2018 Jan; 17():1533033818809694. PubMed ID: 30376767
[TBL] [Abstract] [Full Text] [Related]
7. Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer.
Storebjerg TM; Strand SH; Høyer S; Lynnerup AS; Borre M; Ørntoft TF; Sørensen KD
Clin Epigenetics; 2018 Aug; 10(1):105. PubMed ID: 30086793
[TBL] [Abstract] [Full Text] [Related]
8. Trends in Obesity Prevalence in Adults With a History of cancer: Results From the US National Health Interview Survey, 1997 to 2014.
Greenlee H; Shi Z; Sardo Molmenti CL; Rundle A; Tsai WY
J Clin Oncol; 2016 Sep; 34(26):3133-40. PubMed ID: 27458295
[TBL] [Abstract] [Full Text] [Related]
